Abstract:OBJECTIVE:As a subgroup of lung cancer, small cell lung cancer (SCLC) is characterized by a short tumor doubling time, high rates of early occurred distant cancer spread and poor outcomes. Our study aimed to identify novel molecular markers associated with SCLC prognosis.METHODS:Microarray data from the Gene Expression Omnibus (GEO) database of SCLC tumors and paired normal tissues were obtained. In the dataset, Differentially expressed genes (DEGs) which were identified by comparing gene expression between normal lung and SCLC samples, were screened using the R language. The STRING database was used to map protein-protein interaction (PPI) networks, and these were visualized with the Cytoscape software. Go enrichment analysis and prediction were performed using the Metascape database and the results were visualized. Autophagy-related prognostic genes were identified by univariate COX regression analysis. Subsequently, stepwise model selection using the Akaike information criterion (AIC) and multivariate COX regression model was performed to construct DEGs signature. Survival receiver operating characteristic (ROC) analysis was used to assess the performance of survival prediction. At last, we evaluated the differences in drug sensitivity of the two groups of patients to common chemotherapeutic drugs and small-molecule targeted drugs.RESULTS:A total of 441 identified DE genes, including 412 downregulated and 29 upregulated genes were identified. GO enrichment analyses showed that DEGs were significantly enriched in the collagen-containing extracellular matrix and extracellular matrix organization. 16 genes were individually associated with OS in univariate analyses. The high expression of 6 genes (HIST1H4L, RP11-16O9.2, SNORA71A, SELV, FAM66A and BRWD1-AS1)) was associated with the poor prognosis of SCLC patients. To predict patients' outcomes, we developed an individual's risk score model based on the 6 genes. We found that SCLC patients with a low-risk score had significantly better survival than those with a high-risk score. What's more, association analysis between clinicopathological factors and gene signature showed the risk score was higher in patients with higher clinical stage or T stage. What's more, the patients in the high-risk score group had better treatment effects for etoposide and docetaxel. This suggests that our model can guide clinical treatment decisions.CONCLUSION:A novel six-gene signature was determined for prognostic prediction in SCLC. Our findings may provide new insights into the precise treatment and prognosis prediction of SCLC.

Prognostic Gene Signatures for Lung Adenocarcinoma Using Digital Multiplexed Gene Expression in Formalin-Fixed Paraffin Embedded Tissue.

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

A Robust Gene Expression-Based Prognostic Risk Score Predicts Overall Survival of Lung Adenocarcinoma Patients.

A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma

A Robust Six-Gene Prognostic Signature for Prediction of Both Disease-Free and Overall Survival in Non-Small Cell Lung Cancer

Understanding Prognostic Gene Expression Signatures in Lung Cancer

A Novel 12-Gene Signature As Independent Prognostic Model in Stage IA and IB Lung Squamous Cell Carcinoma Patients

A Bioinformatics-Based Analysis of an Cuproptosis and Ferroptosis-Related Gene Signature Predicts the Prognosis of Patients with Lung Adenocarcinoma

A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma

5-Mrna-based Prognostic Signature of Survival in Lung Adenocarcinoma

Identification of a four-gene panel predicting overall survival for lung adenocarcinoma

Integration and Deconvolution Methodology Deciphering Prognosis-Related Signatures in Lung Adenocarcinoma.

Twenty-gene-based prognostic model predicts lung adenocarcinoma survival

Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.

Development And Validation Of A Seven-Gene Signature For Predicting The Prognosis Of Lung Adenocarcinoma

Identification of Six Novel Prognostic Gene Signatures As Potential Biomarkers in Small Cell Lung Cancer.

Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies

A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients with Lung Adenocarcinoma